Biosimilar

Biosimilar refers to a biological product that is highly similar to an approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. Unlike generic small molecule medicines, biosimilars cannot be identical copies due to inherent variability in biological manufacturing systems. Demonstrating biosimilarity requires a totality of evidence approach integrating extensive analytical comparisons, functional testing, and targeted clinical studies.

The biopharmaceutical industry has expanded biosimilar development to improve patient access to high value biologic therapies while supporting healthcare system sustainability. Manufacturers conduct comprehensive comparability exercises evaluating structure, post-translational modifications, biological activity, and immunogenicity potential relative to the reference product. Regulatory pathways for biosimilars differ across jurisdictions but generally emphasise analytical similarity as the primary foundation for approval. Successful biosimilar programmes require robust manufacturing control strategies and consistent quality performance to maintain similarity throughout commercial supply, while market adoption depends on clinician confidence, reimbursement policies, and interchangeability considerations.